Zerion News

February 15, 2024

dsm-firmenich and Zerion Pharma form a partnership to develop improved cannabinoids

First Cannabidiol drug formulation from partnership to enter clinical studies in 2024.

October 17, 2023

Zerion Pharma featured in Pharmaceutical Technology

Zerion Pharma is featured as an innovative start-up by Pharmaceutical Technology in their ‘Trends in Formulation 2023’ eBook, October 2023.

September 25, 2023

Zerion Pharma A/S elects Carl-Åke Carlsson as Chairman of the Board

September 25, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces that the Company has elected Mr. Carl-Åke Carlsson as its new Chairman of the Board of Directors.

September 1, 2023

Zerion Pharma A/S appoints Mads Aaboe Jensen as Vice President, Business Development

September 1, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces that the Company has strengthened its management team with the appointment of Dr. Mads Aaboe Jensen as Vice President Business

June 8, 2023

Zerion Pharma’s Dispersome® technology published in two peer-reviewed papers through partnerships with pharmaceutical companies

June 8, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces the publication of joint experimental work on its Dispersome® technology in the International Journal of Pharmaceutics and ...

August 29, 2022

Zerion Pharma and Insud Pharma announce collaboration to develop Dispersome® formulations of marketed drug products

AUGUST 29, 2022 (COPENHAGEN, Denmark). The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop

Zerion Pharma in Press